Weber et al. reported that anti-PD-1 (Pembrolizumab) when in combination with mRNA neoantigen vaccines reduced 44% recurrence risk in patients with resected melanoma, compared to anti-PD-1 monotherapy alone [45]. The gene discussed is PDCD1; the disease is melanoma.